Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Accounts Payables (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Accounts Payables readings, the most recent being $137000.0 for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 51.59% to $137000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $137000.0, a 51.59% decrease, with the full-year FY2025 number at $137000.0, down 51.59% from a year prior.
  • Accounts Payables hit $137000.0 in Q4 2025 for Avalo Therapeutics, down from $474000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.9 million in Q1 2021 to a low of $137000.0 in Q4 2025.
  • Median Accounts Payables over the past 5 years was $1.6 million (2022), compared with a mean of $2.4 million.
  • Biggest five-year swings in Accounts Payables: soared 337.01% in 2021 and later tumbled 84.52% in 2023.
  • Avalo Therapeutics' Accounts Payables stood at $3.4 million in 2021, then decreased by 14.46% to $2.9 million in 2022, then crashed by 84.52% to $446000.0 in 2023, then plummeted by 36.55% to $283000.0 in 2024, then tumbled by 51.59% to $137000.0 in 2025.
  • The last three reported values for Accounts Payables were $137000.0 (Q4 2025), $474000.0 (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.